Free Trial
NASDAQ:KZIA

Kazia Therapeutics (KZIA) Stock Price, News & Analysis

Kazia Therapeutics logo
$3.82 -0.11 (-2.80%)
Closing price 05/2/2025 03:52 PM Eastern
Extended Trading
$3.83 +0.01 (+0.26%)
As of 05/2/2025 06:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Kazia Therapeutics Stock (NASDAQ:KZIA)

Key Stats

Today's Range
$3.77
$4.28
50-Day Range
$3.09
$5.90
52-Week Range
$2.86
$79.00
Volume
48,423 shs
Average Volume
173,967 shs
Market Capitalization
$3.85 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$57.50
Consensus Rating
Buy

Company Overview

Kazia Therapeutics Limited operates as an oncology-focused biotechnology company. The company's lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.

Kazia Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
58th Percentile Overall Score

KZIA MarketRank™: 

Kazia Therapeutics scored higher than 58% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Kazia Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Kazia Therapeutics has only been the subject of 1 research reports in the past 90 days.

  • Read more about Kazia Therapeutics' stock forecast and price target.
  • Percentage of Shares Shorted

    0.27% of the float of Kazia Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Kazia Therapeutics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Kazia Therapeutics has recently decreased by 83.62%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Kazia Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Kazia Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.27% of the float of Kazia Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Kazia Therapeutics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Kazia Therapeutics has recently decreased by 83.62%, indicating that investor sentiment is improving significantly.
  • MarketBeat Follows

    2 people have added Kazia Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Kazia Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 1.00% of the stock of Kazia Therapeutics is held by insiders.

  • Percentage Held by Institutions

    Only 30.89% of the stock of Kazia Therapeutics is held by institutions.

  • Read more about Kazia Therapeutics' insider trading history.
Receive KZIA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kazia Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

KZIA Stock News Headlines

Kazia Therapeutics sells IP, trademarks rights to Cantrixil for $1M
Buffett’s favorite chart just hit 209% – here’s what that means for gold
A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the quiet buildup behind the scenes. Now, in just days, the floodgates are set to open. The greatest investor of all time is about to validate what Garrett Goggin has been saying for months: Gold is entering a once-in-a-generation mania. Front-running Buffett has never been more urgent — and four tiny miners could be your ticket to 100X gains.
Kazia Therapeutics announces research grant awarded from MJFF
Kazia Therapeutics initiated with a Buy at Maxim
See More Headlines

KZIA Stock Analysis - Frequently Asked Questions

Kazia Therapeutics' stock was trading at $8.85 at the start of the year. Since then, KZIA shares have decreased by 56.8% and is now trading at $3.82.
View the best growth stocks for 2025 here
.

Shares of Kazia Therapeutics reverse split on the morning of Monday, October 28th 2024. The 1-10 reverse split was announced on Tuesday, October 15th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, October 25th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Shares of KZIA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Kazia Therapeutics investors own include NVIDIA (NVDA), Adobe (ADBE), Broadcom (AVGO), Arista Networks (ANET), ServiceNow (NOW), Meta Platforms (META) and Advanced Micro Devices (AMD).

Company Calendar

Today
5/04/2025
Next Earnings (Estimated)
5/05/2025
Fiscal Year End
6/30/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:KZIA
Previous Symbol
ASX:KZA
Employees
12
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$57.50
High Stock Price Target
$100.00
Low Stock Price Target
$15.00
Potential Upside/Downside
+1,405.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$2.31 million
Price / Cash Flow
N/A
Book Value
($1.97) per share
Price / Book
-1.94

Miscellaneous

Free Float
4,986,000
Market Cap
$3.85 million
Optionable
Optionable
Beta
2.49
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:KZIA) was last updated on 5/4/2025 by MarketBeat.com Staff
From Our Partners